A detailed history of Parallel Advisors, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 1,043 shares of VKTX stock, worth $53,745. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,043
Holding current value
$53,745
% of portfolio
0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$49.84 - $70.47 $51,983 - $73,500
1,043 New
1,043 $66,000
Q1 2024

May 06, 2024

BUY
$17.4 - $94.5 $3,427 - $18,616
197 New
197 $16,000
Q2 2022

Aug 01, 2022

SELL
$2.11 - $3.15 $3,070 - $4,583
-1,455 Reduced 93.69%
98 $0
Q2 2020

Jul 16, 2020

BUY
$4.35 - $8.08 $6,755 - $12,548
1,553 New
1,553 $11,000
Q1 2020

Apr 27, 2020

SELL
$3.45 - $7.95 $5,409 - $12,465
-1,568 Closed
0 $0
Q3 2019

Nov 01, 2019

BUY
$6.55 - $8.6 $10,270 - $13,484
1,568 New
1,568 $11,000
Q4 2018

Feb 05, 2019

SELL
$7.16 - $16.21 $0 - $0
0 Closed
0 $0
Q3 2018

Nov 01, 2018

BUY
$9.7 - $19.65 $0 - $0
0 New
0 $0

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.95B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.